Among them, the small inhibitor SR-18292 improved the metabolic outcome of diabetes type 2, a condition frequently associated with MASLD and its sequelae, by blocking the gluconeogenic pathway and, more in particular, displacing the interaction between Pgc1α and Hnf4α.40 Here, PPARGC1A is linked to type 2 diabetes mellitus.